Gencellmed
Latest round
- Series A
Last raised
- Mar 2021
Total raised
- $5.3M
Investors
- 6
About Gencellmed
, operates as a developer of various technologies for gene therapy. Gencellmed offers a self-targeting adapter and double targeting platform that provide therapeutic solutions for the treatment of cancer. The company uses SMART™ platform technology and therapeutic virus engineering technology that infects disease cells and produces therapeutic viruses that help the patient’s immune system synergize to destroy disease cells. The company’s pipelined platforms are GCM-101, GCM-201, and GCM-301 used for the treatment of ovarian cancer, and pancreatic cancer, respectively.
Who invested in Gencellmed
6 investors across 1 round
See all investors in Gencellmed
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Mar 31, 2021
Amount
$5.3M
Investors
Questions about Gencellmed
Who invested in Gencellmed?
Gencellmed has 6 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Gencellmed raised?
Gencellmed has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Gencellmed last raise money?
Gencellmed's most recent round on record is a Series A, in Mar 2021.
What does Gencellmed do?
, operates as a developer of various technologies for gene therapy.
Where is Gencellmed headquartered?
Gencellmed is headquartered in Seoul, South Korea.
Which VCs invest in companies like Gencellmed?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Gencellmed's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Gencellmed? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.